Successful preferential knockdown of the FOP ACVR1 allele paves the way for in vivo testing and ultimately a new treatment agent for FOP patients that can eventually halt the progression of the disease. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.